Skip to main content
Clinical Trials/NCT00342381
NCT00342381
Completed
Phase 2

Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation

University of Aarhus1 site in 1 country120 target enrollmentJune 2006

Overview

Phase
Phase 2
Intervention
3,4-diaminopyridine
Conditions
Multiple Sclerosis
Sponsor
University of Aarhus
Enrollment
120
Locations
1
Primary Endpoint
Subjective fatigue (FSS)
Status
Completed
Last Updated
18 years ago

Overview

Brief Summary

The purpose of this study is to investigate fatigue in patients with multiple sclerosis (MS) and to determine the correlation between the symptom and cerebral changes.

Detailed Description

Only recruiting from: Department of Neurology, Aarhus University Hospital, Denmark

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
December 2007
Last Updated
18 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Relapsing remitting-multiple sclerosis (RR-MS) according to Poser criteria
  • EDSS: max 3.5
  • Right handed
  • Normal function of the right hand

Exclusion Criteria

  • Disease interfering with MS
  • Known dementia
  • Drug or alcohol abuse
  • Treatment with psychoactive drugs within one week before study entry
  • Major changes of medical treatment within 3 weeks before study entry
  • Attack within 4 weeks before study entry
  • Pregnancy
  • Conditions interfering with 3,4-diaminopyridine treatment
  • Conditions interfering with MRI
  • Conditions interfering with transcranial magnetic stimulation

Arms & Interventions

3.4 diaminopyridine

Single dose 3,4 diaminopyridine

Intervention: 3,4-diaminopyridine

Placebo

Two tablets identical to active treatment

Intervention: Placebo

Outcomes

Primary Outcomes

Subjective fatigue (FSS)

Time Frame: Weeks

Maximal voluntary isometric contraction, central activation before and after exercise

Time Frame: at the time of investigation

Digit Symbol-Coding scores

Time Frame: Weeks

Changes in normal appearing white matter and normal appearing gray matter (MRS-, MTI- and DTI- parameters)

Time Frame: at the time of MRI

Cortical atrophy

Time Frame: at the time of MRI

Intracortical inhibition/facilitation determined by transcranial magnetic stimulation (+/- 3,4-diaminopyridine)

Time Frame: at the time of investigation

Secondary Outcomes

  • 6 minute walk test(at the time of investigation)
  • Subjective fatigue (MFI-20, Danish version)(Weeks)
  • Rapid voluntary twitches(at the time of investigation)
  • 9-hole peg test(at the time of investigation)
  • WAIS/WMS tests(at the time of investigation)
  • WHO-5 Questionnaire(at the time of investigation)
  • Major Depression Inventory(at the time of investigation)
  • Lesion load(at the time of MRI)
  • Whole brain atrophy(at the time of MRI)
  • Subjective fatigue (VAS)(at the time of investigation)

Study Sites (1)

Loading locations...

Similar Trials